Zydus receives final approval from the USFDA for Teriflunomide Tablets

Zydus receives final approval from the USFDA for Teriflunomide Tablets ________________________________________________________________ Ahmedabad, December 1, 2018 Zydus Cadila has received the final approval from the USFDA to market Teriflunomide Tablets (US RLD- AUBAGIO), 7 mg and 14 mg. It will be manufactured at the group’s formulations manufacturing facility at SEZ, Ahmedabad. Teriflunomide is used to treat relapsing forms of multiple sclerosis (MS). It is not a cure for MS but is thought to work by decreasing certain immune system cells (lymphocytes) which can attack the nerves in brain and spinal cord. This helps decrease the number of flare -ups (relapses) and may help slow down physical problems caused by MS. The group now has 2 37 approvals and has so far filed over 340 ANDAs since the commencement of the filing process in FY 2003-04. About Zydus Cadila Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies. The group employs over 23,000 people worldwide and is dedicated to creating healthier communities globally. Zydus aspires to be a research-based pharmaceutical company by 2020. ***

The release as fetched from its publisher. zyduslife.com ↗